Ananoymous: "Xencor Initiates Two Phase 2 Trials of XmAb5871 in IgG4-Related Disease and Systemic Lupus Erythematosus", , 7 March 2016 (2016-03-07), XP055395505, Retrieved from the Internet: URL:http://files.shareholder.com/downloads /AMDA-2B2V8N/4918247024x0x879742/C3D831BF- 5DB6-4236-9585-963A1B0E061C/XNCR_News_2016 _3_7_General_Releases.pdf [retrieved on 2017-08-02] (B1)

Anonymous: "Antibodies by Design Xencor R&D Day Welcome", , 26 June 2015 (2015-06-26), pages 1-81, XP055395666, Retrieved from the Internet: URL:http://files.shareholder.com/downloads /AMDA-2B2V8N/0x0x836956/AA64F6CD-17CB-4C8F -9B75-C23F8891E90A/Xencor_Analyst_Day_Pres entation_-_FINAL.pdf [retrieved on 2017-08-03] (B1)

Anonymous: "Xencor Presents Preliminary Data from an Ongoing, Open-label, Phase 2 Study of XmAb 5871 in IgG4-Related Disease (IgG4-RD) at the American College of Rheumatology 2016 Annual Meeting", , 13 November 2016 (2016-11-13), XP055395560, Retrieved from the Internet: URL:http://files.shareholder.com/downloads /AMDA-2B2V8N/4918247024x0x917214/30B79CD2- 6FBC-412A-8FF1-09559D7D66F8/XNCR_News_2016 _11_13_General_Releases.pdf [retrieved on 2017-08-02] (B1)

Calif Monrovia ET AL: "Xencor Reports Top-line XmAb 5871 Phase 1b/2a Results Showing Promising Clinical Activity in Rheumatoid Arthritis -33% rate of DAS28-CRP remission or low disease activity reported in Phase 2a cohort- -Autoimmune disease-modifying activity demonstrated by targeting FcgRIIb (CD32b)- -Clinical trial fo", January, 29 January 2015 (2015-01-29), XP055395592, Retrieved from the Internet: URL:http://files.shareholder.com/downloads /AMDA-2B2V8N/4918247024x0x805742/C198CB25- EF2D-4810-8619-641A0E56BB31/XNCR_News_2015 _1_29_General_Releases.pdf [retrieved on 2017-08-02] (B1)

DÁNIEL SZILI ET AL: "Suppression of innate and adaptive B cell activation pathways by antibody coengagement of Fc[gamma]RIIb and CD19", MABS, vol. 6, no. 4, 1 July 2014 (2014-07-01), pages 991-999, XP055395368, US ISSN: 1942-0870, DOI: 10.4161/mabs.28841 (B1)

Fink Katja ET AL: "Origin and Function of Circulating Plasmablasts during Acute Viral Infections", Frontiers in Immunology, vol. 3, 12 April 2012 (2012-04-12), XP093031485, DOI: 10.3389/fimmu.2012.00078 (B1)

WO-A1-2014/113510 (B1)

John H Stone ET AL: "Session Title: Miscellaneous Rheumatic and Inflammatory Diseases I Session Type: ACR Concurrent Abstract Number 940 Session A Trial of XmAb 5871, a Reversible Inhibitor of CD19+ Cells, in IgG4-Related Disease Meeting: 2016 ACR/ARHP Annual Meeting", , 28 September 2016 (2016-09-28), XP055395585, Retrieved from the Internet: URL:http://pdfcrowd.com/url_to_pdf/?use_pr int_media=1 [retrieved on 2017-08-02] (B1)

Mackay Meggan ET AL: "Selective dysregulation of the Fc[gamma]IIB receptor on memory B cells in SLE", Journal of Experimental Medicine, vol. 203, no. 9, 4 September 2006 (2006-09-04), pages 2157-2164, XP93031479, US ISSN: 0022-1007, DOI: 10.1084/jem.20051503 Retrieved from the Internet: URL:https://rupress.org/jem/article-pdf/20 3/9/2157/1158640/2157.pdf> (B1)

PILAR BRITO-ZERÓN ET AL: "IgG4-related disease: Advances in the diagnosis and treatment", BAILLIERE'S BEST PRACTICE AND RESEARCH. CLINICAL REUMATOLOGY, vol. 30, no. 2, 1 April 2016 (2016-04-01), pages 261-278, XP055395374, GB ISSN: 1521-6942, DOI: 10.1016/j.berh.2016.07.003 (B1)

SEUNG Y. CHU ET AL: "Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Anti-CD19 Antibody That Coengages B Cell Antigen Receptor Complex and Fc[gamma] Receptor IIb Inhibitory Receptor : Suppression of RA B Cells by Coengagement of Fc[gamma]RIIb and CD19", ARTHRITIS & RHEUMATOLOGY (HOBOKEN), vol. 66, no. 5, 1 May 2014 (2014-05-01), pages 1153-1164, XP055395351, US ISSN: 2326-5191, DOI: 10.1002/art.38334 (B1)

San Segundo David ET AL: "Regulatory B-Cells in Transplantation", Antibodies, vol. 2, no. 4, 1 December 2013 (2013-12-01), pages 587-597, XP93031475, CH ISSN: 2073-4468, DOI: 10.3390/antib2040587 (B1)

WO-A1-2008/150494 (B1)

J. L. KARNELL ET AL: "CD19 and CD32b Differentially Regulate Human B Cell Responsiveness", THE JOURNAL OF IMMUNOLOGY, vol. 192, no. 4, 17 January 2014 (2014-01-17), pages 1480-1490, XP055395356, US ISSN: 0022-1767, DOI: 10.4049/jimmunol.1301361 (B1)